Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: Daunorubicin formulation, in bone marrow xenografts

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1214-1223

  Lim, Wah Seng ^a   Tardi, Paul G ^a   Dos Santos, Nancy ^a   Xie, Xiaowei ^a   Fan, Mannie ^a   Liboiron, Barry D ^a   Huang, Xiaoping ^a   Harasym, Troy O ^a   Bermudes, David ^a   Mayer, Lawrence D ^a  

^a Celator Pharmaceuticals Corp   (Canada)

Author keywords

Acute leukemia; Drug delivery; Efficacy; Pharmacodynamics; Synergy

Indexed keywords

CPX 351; CYTARABINE; CYTARABINE PLUS DAUNORUBICIN; DAUNORUBICIN; LIPOSOME; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; MAXIMUM TOLERATED DOSE; MOUSE; MOUSE STRAIN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; XENOGRAFT;

EID: 77955280642     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.015     Document Type: Article

References (38)

1. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
2. Bassan R., Lerede T., Rambaldi A., et al. The role of anthracyclines in adult acute lymphoblastic leukaemia. Leukemia 1996, 10(Suppl 2):s58-s61.
3. Rowe J.M. Optimal management of adults with ALL. Br J Haematol 2009, 144:468-483.
4. Tardi P., Johnstone S., Harasym N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
5. Mayer L.D., Harasym T.O., Tardi P.G., et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006, 5:1854-1863.
6. Adams D.J., Sandvold M.L., Myhren F., Jacobsen T.F., Giles F., Rizzieri D.A. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008, 49:786-797.
7. Feldman E.J.L.J., Kolitz J.E., Ritchie E., et al. Phase I study of a liposomal carrier (CPX-351) containing a synergistic, fixed molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) in advanced leukemias. Blood (ASH Annual Meeting Abstracts) 2008, 112:2984.
8. Braess J., Pfortner J., Kern W., Hiddemann W., Schleyer E. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 1999, 78:514-520.
9. Houghton P.J., Mirro J., Goorha R.M., Raimondi S.C., Fridland A., Houghton J.A. Growth and differentiation of a human T-cell leukemia cell line, CCRF-CEM, grafted in mice. Cancer Res 1989, 49:7124-7131.
10. Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965, 18:522-529.
11. Cattan A.R., Douglas E. The C.B.17 scid mouse strain as a model for human disseminated leukaemia and myeloma in vivo. Leuk Res 1994, 18:513-522.
12. Cai J., Damaraju V.L., Groulx N., et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008, 68:2349-2357.
13. Kim M., Kim J., Lim J., Kim Y., Han K., Kang C.S. Use of an automated hematology analyzer and flow cytometry to assess bone marrow cellularity and differential cell count. Ann Clin Lab Sci 2004, 34:307-313.
14. Borowitz M.J., Guenther K.L., Shults K.E., Stelzer G.T. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993, 100:534-540.
15. Gimble J.M., Robinson C.E., Wu X., Kelly K.A. The function of adipocytes in the bone marrow stroma: an update. Bone 1996, 19:421-428.
16. Islam A., Catovsky D., Galton D.A. Histological study of bone marrow regeneration following chemotherapy for acute myeloid leukaemia and chronic granulocytic leukaemia in blast transformation. Br J Haematol 1980, 45:535-540.
17. Wiley J.S., Taupin J., Jamieson G.P., Snook M., Sawyer W.H., Finch L.R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985, 75:632-642.
18. Kessel D., Hall T.C., Rosenthal D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res 1969, 29:459-463.
19. Tidefelt U., Sundman-Engberg B., Paul C. Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells. Cancer Chemother Pharmacol 1991, 29:7-12.
20. Dick F.R., Burns C.P., Weiner G.J., Heckman K.D. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML). Hematol Pathol 1995, 9:95-106.
21. Cripe L.D., Hinton S. Acute myeloid leukemia in adults. Curr Treat Options Oncol 2000, 1:9-17.
22. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.
23. McCauley D.L. Treatment of adult acute leukemia. Clin Pharm 1992, 11:767-796.
24. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
25. Forssen E.A., Coulter D.M., Proffitt R.T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992, 52:3255-3261.
26. Kim P, Gerhard G, Harasym T, et al. Improved selectivity against acute myeloid leukemia (AML) blasts over normal hematopoietic progenitors for cytarabine:daunorubicin delivered as CPX-351 liposome injection. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2071.
27. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995, 270:16221-16224.
28. Kamps J.A., Scherphof G.L. Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 1998, 32:81-97.
29. Chung N.S., Wasan K.M. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 2004, 56:1315-1334.
30. Amin K., Wasan K.M., Albrecht R.M., Heath T.D. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. J Pharm Sci 2002, 91:1233-1244.
31. Belov L., de la Vega O., dos Remedios C.G., Mulligan S.P., Christopherson R.I. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 2001, 61:4483-4489.
32. Xu Y., McKenna R.W., Wilson K.S., Karandikar N.J., Schultz R.A., Kroft S.H. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia 2006, 20:1321-1324.
33. Casasnovas R.O., Slimane F.K., Garand R., et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003, 17:515-527.
34. Banker D.E., Mayer S.J., Li H.Y., Willman C.L., Appelbaum F.R., Zager R.A. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004, 104:1816-1824.
35. Scherf U., Ross D.T., Waltham M., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244.
36. Greenwalt D.E., Lipsky R.H., Ockenhouse C.F., Ikeda H., Tandon N.N., Jamieson G.A. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 1992, 80:1105-1115.
37. Barth H., Schnober E.K., Neumann-Haefelin C., et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008, 82:3466-3479.
38. Lancet JE, Feldman EJ, Kolitz JE, et al. Phase IIb Randomized Study of CPX-351 vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report. Blood (ASH Annual Meeting Abstracts), 2009; 114: 1033.